Skip to main content
    B

    Bicycle Therapeutics Ltd (BCYC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.20
    +0.02 (+0.63%)

    Market Cap: $222.90M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Bicycle Therapeutics Ltd (BCYC) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Bicycle Therapeutics (BCYC) has a market cap of $222.90M. Revenue grew 194.75% over the last 12 months from the 12 months before. It kept -169.75% of revenue as net income over the last 12 months.

    Total Valuation

    Market Cap$222.90M
    Latest price (Nov 17, 2026)$3.20

    Key Dates

    The next earnings report is expected on Mar 15, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 15, 2027 (expected)
    Last Earnings DateOct 29, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.25% in the quarter ended Sep 30, 2026 and grew 0.72% a year over 2 years.

    Shares Outstanding69.98M
    Shares Change (YoY)+0.98%
    Shares Change (QoQ)+0.25%
    Share Count Growth (2Y CAGR)+0.72%

    Valuation Ratios

    Sales and book value multiples are 2.7x and 0.4x. Its year-end P/S ranged from 6.8x to 132.3x from 2019 to 2025.

    P/S Ratio2.7x
    Forward P/S5.9x
    P/B Ratio0.4x

    Valuation history and multiples

    Price Statistics

    The stock is down 50.62% over 52 weeks and trades 12.57% below its 50-day average.

    Beta (1Y)1.69
    52-Week Change-50.62%
    1-Month Change-9.48%
    3-Month Change-22.71%
    6-Month Change-26.44%
    5-Year Change-92.88%
    Total Return (1Y)-50.62%
    Total Return (3Y CAGR)-38.63%
    Total Return (5Y CAGR)-44.08%
    Return vs SPY (1Y)-62.10%
    Max Drawdown (1Y)-57.71%
    Max Drawdown (3Y)-88.44%
    Sharpe Ratio (1Y)-1.40
    Correlation with SPY (1Y)0.46
    50-Day Average$3.66
    200-Day Average$4.37
    52-Week Range$3.07 to $7.83
    RSI (14 Days)36.1
    Average Volume (20 Days)407.89K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 12.09x current liabilities.

    Current Ratio12.09x
    Quick Ratio12.09x
    Interest Coverage-715.98x

    Returns and Efficiency

    Return on equity is -28.06% over the last 12 months, against a 5-year average of -33.37%.

    Return on Equity (ROE)-28.06%
    Return on Assets (ROA)-25.00%
    Return on Capital Employed (ROCE)-26.57%
    ROE (5Y Average)-33.37%
    ROA (5Y Average)-23.98%
    ROIC (5Y Average)-30.55%
    Asset Turnover0.13x
    Receivables Turnover1.67x

    Scores

    BCYC has an Altman Z-Score of 0.03, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score0.03
    Altman Z ZoneDistress
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $83.53M over the last 12 months.

    Revenue$83.53M
    Revenue Growth (YoY)+194.75%
    Gross Profit$83.53M
    Operating Income-$158.28M
    Pretax Income-$139.09M
    Net Income-$141.79M
    EBITDA-$134.29M
    EBIT-$138.90M
    Reported EPS (TTM)-$2.03

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 89.09% of the $567.18M in total assets.

    Cash and Equivalents$469.93M
    Working Capital$493.10M
    Shareholder Equity$505.28M
    Total Assets$567.18M
    Total Liabilities$61.90M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $1.86M of capital spending, operating cash flow left -$176.70M of free cash flow.

    Operating Cash Flow-$174.85M
    Capital Expenditures$1.86M
    Free Cash Flow-$176.70M
    FCF Per Share-$3.49
    Depreciation and Amortization$4.61M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -189.50%.

    Gross Margin100.00%
    Operating Margin-189.50%
    Pretax Margin-166.52%
    Net Margin-169.75%
    EBITDA Margin-160.78%
    EBIT Margin-166.29%
    FCF Margin-211.55%

    Growth

    Revenue grew 71.21% a year over 3 years.

    Revenue Growth (3Y CAGR)+71.21%
    Revenue Growth (5Y CAGR)+47.52%

    Revenue and profit by year

    Dividends and Yields

    BCYC does not pay a dividend. Its free cash flow yield is -78.91%.

    FCF Yield-78.91%
    Shareholder Yield0.00%

    Peer Position

    Against 6 similar companies, BCYC has the lowest P/S.

    P/S Ratio2.7x vs 11.4x median
    Revenue Growth (Trailing 4 Quarters, YoY)+194.75% vs -51.34% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 18.42% a year over the next 5 fiscal years.

    Revenue Growth Forecast (5Y CAGR)+18.42%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About BCYC

    What is BCYC's market cap?

    Bicycle Therapeutics has a market cap of $222.90M.

    How many shares of BCYC are outstanding?

    Bicycle Therapeutics has 69.98M shares outstanding. The count is up 0.98% from a year earlier.

    Does BCYC pay a dividend?

    No. Bicycle Therapeutics does not pay a dividend.